Dental Implants
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient aged between 18 and 75 years, of both sexs, with total edentulism of the mandible and/or maxilla; patients with sufficient bone volume and height for implant placement
Exclusion criteria
Exclusion criteria: Use of antibiotics; continuous-use anti-inflammatories; phenytoin; cyclosporine; bisphosphonates in the 6 months prior to the study; presence of systemic changes or active infectious disease (diabetes, heart disease, hepatitis, etc.); smoking; pregnancy; breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: It is expected to quantitatively evaluate, through the Luminex/MAGpix platform, the concentration of vascular/osteoblast/clastogenic mediators/markers (VEGF-A, PLGF, endothelin-1, DKK1, OC, OPN, OPG, sclerotin, BMP-9, EGF, FGF, Periostin, TRAP5, TWEAK, osteonectin, IL-1ß, IL-6, TNF-a, RANKL) in the peri-implant fluid of the inserted implants;Outcome found 1: It was observed that TNF-a levels were significantly lower in the test group (P<0.05), with no statistically significant differences for the other markers analyzed (P>0.05) | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: It is expected to evaluate the insertion torque at the time of surgery and the primary stability quotient levels of dental implants with modified macrogeometry, after implant placement, and after 45 and 90 days, in comparison with conventional implants;Outcome found 2: It was observed that the insertion torque was significantly lower in the test group (P<0.05). The results demonstrated no significant difference in primary stability between the groups (P>0.05) | — |
Countries
Brazil
Contacts
Universidade Paulista